| Name | Title | Contact Details |
|---|
Accumulus Synergy is a global, non-profit organization that is developing a transformative data exchange platform that aims to enable enhanced collaboration and efficiency between life sciences organizations and global health authorities, while also affording users the ability to extract dynamic, data-driven insights from knowledge management. Sponsored by leading biopharmaceutical companies, Accumulus Synergy was formed in 2020 to create innovative solutions that can reduce regulatory review times and transform global data exchange. The non-profit company is creating a first-of-its-kind cloud-based platform between the biopharmaceutical industry and health authorities worldwide. The single-platform approach aims to improve speed, transparencies and efficiencies in the regulatory process by leveraging advanced technology and tools for data exchange. This will help reduce the cost of innovation and ultimately bring patients safe and effective medicines faster.
At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day. We believe the journey to improve women`s health is critical to achieving a healthier world. We are united in our drive to better support the health of women within our company and around the globe. Together, we work toward our goal of finding solutions for the healthcare issues that matter most to her, today and every day.
Chalmers and Kubeck North is a Salem, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company`s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.
EDAP TMS currently develops and markets high-technology medical devices for the treatment of certain types of urological disorders including the ablation of localized prostate cancer tumors using HIFU (High Intensity Focused Ultrasound) technology and ...